Ajanta Pharma share news, announcements and annual reports
NSE: AJANTPHARMBSE: 532331Pharmaceuticals & BiotechnologyMid Cap
Ajanta Pharma Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed May 2000 on NSE, Jun 2000 on BSE
Last close ₹3,353.60down ₹27.40 (0.81%)BSE ₹3,348.60
Share price at the NSE close on 27 Oct 2026. Previous close ₹3,381.00.
27 Oct: open ₹3,385.00, high ₹3,529.30, low ₹3,330.00
52-week range of traded prices to 27 Oct 2026
₹2,382.00Low, 28 Oct 2025₹3,796.00High, 18 Aug 2026
- Next results date: the board meets on 30 Oct 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹41,906 Cr236th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- 36.93
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 9.26
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 1.79%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it.
- 27.3%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 27.2%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.05
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 1,74,37450.1% delivered
Ajanta Pharma has 810 announcements on record, routine notices left out; 6 in the 30 days to 28 Oct 2026, the latest on 21 Oct 2026.
Next board meeting and results date
As the company gave notice to the exchange.Ajanta Pharma quarterly results
Oct30Fri
The board meets on 30 Oct 2026 to consider financial results
Notice filed 15 Oct 2026
To consider and approve the financial results for the period ended September 30, 2026
Ajanta Pharma annual reports, presentations and earnings calls
The company's own documents, latest first.Ajanta Pharma financials, year by year
Annual reports16
- Annual report, year to Mar 202618 Jun 2026
- Annual report, year to Mar 202518 Jun 2025
- Annual report, year to Mar 20246 Sep 2024
- Annual report, year to Mar 202316 Jun 2023, a zip file
- Annual report, year to Mar 20226 Jul 2022, a zip file
11 earlier reports
- Annual report, year to Mar 202115 Jun 2021, a zip file
- Annual report, year to Mar 202030 Jun 2020, a zip file
- Annual report, year to Mar 201920 Jun 2019, a zip file
- Annual report, year to Mar 20185 Jul 2018, a zip file
- Annual report, year to Mar 20175 Jul 2017, a zip file
- Annual report, year to Mar 20165 Jul 2016, a zip file
- Annual report, year to Mar 201510 Jun 2015, a zip file
- Annual report, year to Mar 20144 Jul 2014, a zip file
- Annual report, year to Mar 201327 Jun 2013, a zip file
- Annual report, year to Mar 201222 Jun 2012, a zip file
- Annual report, year to Mar 20108 Apr 2011, a zip file
Investor presentations17
- Investor Presentation5 Feb 2020
- Investor Presentation5 Nov 2019
- Investor Presentation31 Jul 2019
- Investor Presentation30 Apr 2019
- Investor Presentation30 Jan 2019
12 earlier presentations
- Investor Presentation31 Oct 2018
- Investor Presentation31 Jul 2018, a zip file
- Investor Presentation2 May 2018, a zip file
- Investor Presentation for Q3 201825 Jan 2018, a zip file
- Investor Presentation31 Oct 2017, a zip file
- Investor Presentation9 Aug 2017, a zip file
- Investor Presentation3 May 2017, a zip file
- Investor Presentation24 Jan 2017, a zip file
- Presentation on results being circulated to the investors and analysts.26 Oct 2016, a zip file
- Presentation on results being circulated to the investors and analysts.26 Jul 2016, a zip file
- Investor Presentation Q4 FY 2016.29 Apr 2016, a zip file
- Investor Presentation made to Analysts with respect to the financial results.1 Feb 2016, a zip file
Earnings calls42
- Transcript3 Aug 2026
- Link of Recording30 Jul 2026
- Transcript8 May 2026
- Link of Recording5 May 2026
- Transcript5 Feb 2026
37 earlier call documents
- Link of Recording30 Jan 2026
- Transcript6 Nov 2025
- Link of Recording3 Nov 2025
- Transcript31 Jul 2025
- Link of Recording28 Jul 2025
- Transcript5 May 2025
- Link of Recording30 Apr 2025
- Transcript3 Feb 2025
- Link of Recording30 Jan 2025
- Transcript30 Oct 2024
- Link of Recording28 Oct 2024
- Transcript2 Aug 2024
- Link of Recording30 Jul 2024
- Transcript8 May 2024
- Link of Recording2 May 2024
- Transcript5 Feb 2024
- Link of Recording31 Jan 2024
- Transcript3 Nov 2023
- Link of Recording31 Oct 2023
- Link of Recording31 Oct 2023
- Transcript2 Aug 2023
- Link of Recording27 Jul 2023
- Transcript11 May 2023
- Link of Recording5 May 2023
- Transcript13 Feb 2023
- Link of Recording2 Feb 2023
- Transcript of Analysts/Institutional Investor Meet/Con. Call10 Nov 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call4 Nov 2022
- Transcript of Analysts/Institutional Investor Meet/Con. Call3 Aug 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call29 Jul 2022
- Written transcript of the earnings call held on 10th May 2022 at 5.00 p.m. has been uploaded on the Company's website and can be accessed through the link http://www.ajantapharma.com/AdminData/Results/EarningsC allTranscriptQ4(Jan-Mar)2021-22.pdf14 May 2022
- Recording of Analysts/Institutional Investor Meet/Con. Call conducted on 10th May 202211 May 2022
- Transcript4 Feb 2022
- Audio call recording of the earnings call held on 31st January 2022 at 5.00 p.m. has been uploaded on the Company s website and can be accessed through the link:http://www.ajantapharma.com/AdminData/Results/EarningsCallAudioQ3(Oct-Dec)2021-22.mp331 Jan 2022
- Transcript8 Nov 2021
- Transcript8 Nov 2021
- Link of Recording of Earnings call29 Oct 2021
Ajanta Pharma merger and demerger filings
Filings about a merger, demerger or scheme of arrangement, latest first.
Filings2
- That the Hon ble National Company Law Tribunal, Mumbai Bench ('NCLT') did not deem it fit to approve and sanction the proposed Scheme. The copy of the order pronounced by the Hon'ble NCLT was made available to the Company by the Counsel of the Company on September 07, 2018. The Company is examining the order in detail.10 Sep 2018
- Board of Directors, at its meeting held on March 18, 2017 has inter alia, considered and approved the amalgamation of Gabs Investments Private Limited ( Gabs ) with Ajanta Pharma Limited ( APL ) in consideration for Equity shares of APL. The proposed amalgamation would be carried out vide a Scheme of Amalgamation and Arrangement between Gabs Investments Private Limited and Ajanta Pharma Limited and their respective Shareholders ( the Scheme ) under Sections 230-232 read with Section 52 and Section 66 of the Companies Act, 2013 and other applicable provisions of the Companies Act, 1956 / Companies Act, 2013.20 Mar 2017, a zip file
Ajanta Pharma share news and announcements
Newest first. Page 1 of 17.
Oct 2026
15 Oct · Analysts
15 Oct · Board meeting
Sep 2026
30 Sep · General Updates
Aug 2026
31 Aug · Analysts
File name: “Investorparticipation31082026”
5 Aug · Analysts
Jul 2026
30 Jul · General Updates
30 Jul · Corporate action
30 Jul · Results
21 Jul · Analysts
20 Jul · Analysts
20 Jul · Board meeting
16 Jul · Meeting
2 Jul
Jun 2026
18 Jun · Meeting
15 Jun · General Updates
12 Jun · Analysts
May 2026
19 May · Analysts
19 May · Analysts
5 May · Analysts
5 May
5 May
5 May · Results
Apr 2026
22 Apr
21 Apr · Analysts
21 Apr · Board meeting
Mar 2026
How the price met the news
The latest 30. The first session after each announcement, beside the market.
That dayThe first session's move. The first session's close after the announcement against the close before it, as a per cent change, on prices adjusted for splits and bonuses.Against the Nifty 500Against the Nifty 500. The share's move less the Nifty 500's move the same session, in percentage points (pts).Market median on that newsThe market's median move on that news. The middle first-session move of every listed company that filed the same kind of announcement, half moving more and half less.Five sessionsFive sessions' move. The close five sessions after the announcement against the close before it, as a per cent change.Five sessions against the Nifty 500Five sessions against the Nifty 500. The share's five-session move less the Nifty 500's move over the same five sessions, in percentage points (pts).Volume, times usualVolume, times usual. The session's shares traded divided by the average of the twenty sessions before it.Delivery against usualDelivery against usual. The share of the session's volume delivered into demat accounts, rather than bought and sold again the same day, less its average over the twenty sessions before, in percentage points (pts). Delivery against usual in the glossary
- 30 Jul 2026Resultsup 1.17%+1.2 pts vs Nifty 500market median −0.7% · five sessions +1.2% (−0.4 pts vs Nifty 500) · volume 4.3× usual · delivery −30.9 pts against usual · The announcement
- 5 May 2026Resultsdown 0.11%0.0 pts vs Nifty 500market median −0.7% · five sessions +5.6% (+5.8 pts vs Nifty 500) · volume 1.0× usual · delivery −6.5 pts against usual · The announcement
- 30 Jan 2026Resultsup 3.23%+3.5 pts vs Nifty 500market median −0.7% · five sessions +4.7% (+3.0 pts vs Nifty 500) · volume 1.2× usual · delivery −13.7 pts against usual · The announcement
- 3 Nov 2025Resultsup 3.01%+2.6 pts vs Nifty 500market median −0.7% · five sessions +2.6% (+3.1 pts vs Nifty 500) · volume 2.0× usual · delivery −39.0 pts against usual · The announcement
- 28 Jul 2025Resultsdown 0.62%+0.1 pts vs Nifty 500market median −0.7% · five sessions −3.2% (−1.7 pts vs Nifty 500) · volume 1.1× usual · delivery −21.2 pts against usual · The announcement
- 30 Apr 2025Resultsdown 2.16%−1.8 pts vs Nifty 500market median −0.7% · five sessions −9.7% (−9.5 pts vs Nifty 500) · volume 1.0× usual · delivery +9.1 pts against usual · The announcement
- 31 Jan 2025Resultsup 0.66%−0.7 pts vs Nifty 500market median −0.7% · five sessions +4.1% (+1.8 pts vs Nifty 500) · volume 2.5× usual · delivery +32.3 pts against usual · The announcement
- 29 Oct 2024Dividendup 0.06%−0.6 pts vs Nifty 500market median 0.0% · five sessions +2.1% (+2.7 pts vs Nifty 500) · volume 0.8× usual · delivery −24.5 pts against usual · The announcement
- 30 Jul 2024Resultsup 4.63%+4.4 pts vs Nifty 500market median −0.7% · five sessions +17.5% (+21.1 pts vs Nifty 500) · volume 2.4× usual · delivery −31.6 pts against usual · The announcement
- 18 Jul 2024Board or managers changedup 2.57%+2.5 pts vs Nifty 500market median 0.0% · five sessions +7.0% (+8.3 pts vs Nifty 500) · volume 0.6× usual · delivery −17.3 pts against usual · The announcement
20 earlier announcements
- 28 Jun 2024Buybackup 0.15%+0.1 pts vs Nifty 500market median 0.0% · five sessions −2.8% (−4.5 pts vs Nifty 500) · volume 0.6× usual · delivery +15.1 pts against usual · The announcement
- 21 Jun 2024Buybackup 0.21%+0.5 pts vs Nifty 500market median 0.0% · five sessions −2.4% (−3.5 pts vs Nifty 500) · volume 0.5× usual · delivery +10.3 pts against usual · The announcement
- 4 Jun 2024Buybackdown 1.53%+5.2 pts vs Nifty 500market median 0.0% · five sessions +3.8% (+3.7 pts vs Nifty 500) · volume 1.4× usual · delivery −7.0 pts against usual · The announcement
- 7 May 2024Buybackdown 0.69%+0.4 pts vs Nifty 500market median 0.0% · five sessions −1.4% (+0.3 pts vs Nifty 500) · volume 0.8× usual · delivery −13.5 pts against usual · The announcement
- 3 May 2024Resultsup 6.71%+7.3 pts vs Nifty 500market median −0.7% · five sessions +7.9% (+11.4 pts vs Nifty 500) · volume 29.2× usual · delivery −42.0 pts against usual · The announcement
- 1 Feb 2024Dividendup 0.32%+0.4 pts vs Nifty 500market median 0.0% · five sessions +3.8% (+2.3 pts vs Nifty 500) · volume 4.8× usual · delivery −11.6 pts against usual · The announcement
- 28 Jul 2023Dividendup 4.07%+3.9 pts vs Nifty 500market median 0.0% · five sessions +10.9% (+11.8 pts vs Nifty 500) · volume 17.4× usual · delivery −45.8 pts against usual · The announcement
- 8 May 2023Resultsdown 1.52%−2.5 pts vs Nifty 500market median −0.7% · five sessions −2.7% (−4.0 pts vs Nifty 500) · volume 2.9× usual · delivery +25.8 pts against usual · The announcement
- 20 Apr 2023Buybackdown 0.14%−0.2 pts vs Nifty 500market median 0.0% · five sessions −1.2% (−2.2 pts vs Nifty 500) · volume 0.9× usual · delivery +22.6 pts against usual · The announcement
- 28 Mar 2023Buybackdown 1.26%−0.9 pts vs Nifty 500market median 0.0% · five sessions +7.5% (+4.3 pts vs Nifty 500) · volume 0.3× usual · delivery −16.3 pts against usual · The announcement
- 14 Mar 2023Buybackdown 0.71%0.0 pts vs Nifty 500market median 0.0% · five sessions −3.0% (−2.0 pts vs Nifty 500) · volume 0.5× usual · delivery −5.0 pts against usual · The announcement
- 4 Nov 2022Dividenddown 6.79%−7.1 pts vs Nifty 500market median 0.0% · five sessions −6.7% (−7.7 pts vs Nifty 500) · volume 7.0× usual · delivery −22.5 pts against usual · The announcement
- 28 Feb 2022Buybackdown 0.88%−1.7 pts vs Nifty 500market median 0.0% · five sessions −1.8% (+2.6 pts vs Nifty 500) · volume 3.3× usual · delivery +29.3 pts against usual · The announcement
- 21 Jan 2022Buybackup 2.87%+4.0 pts vs Nifty 500market median 0.0% · five sessions +1.2% (+5.3 pts vs Nifty 500) · volume 0.7× usual · delivery −15.0 pts against usual · The announcement
- 5 Jan 2022Buybackup 1.38%+0.9 pts vs Nifty 500market median 0.0% · five sessions +3.5% (+2.1 pts vs Nifty 500) · volume 0.8× usual · delivery −19.0 pts against usual · The announcement
- 31 Dec 2021Buybackdown 1.21%−2.2 pts vs Nifty 500market median 0.0% · five sessions −1.5% (−4.5 pts vs Nifty 500) · volume 0.6× usual · delivery +6.2 pts against usual · The announcement
- 28 Dec 2021Buybackup 3.95%+3.0 pts vs Nifty 500market median 0.0% · five sessions +1.6% (−1.6 pts vs Nifty 500) · volume 8.0× usual · delivery −31.6 pts against usual · The announcement
- 28 Dec 2020Buybackup 1.02%+0.1 pts vs Nifty 500market median 0.0% · five sessions −1.3% (−3.5 pts vs Nifty 500) · volume 0.9× usual · delivery −3.3 pts against usual · The announcement
- 26 Nov 2020Buybackup 0.03%−0.9 pts vs Nifty 500market median 0.0% · five sessions +2.2% (−0.8 pts vs Nifty 500) · volume 0.9× usual · delivery −16.1 pts against usual · The announcement
- 11 Nov 2020Buybackup 1.36%+0.5 pts vs Nifty 500market median 0.0% · five sessions +1.4% (−1.0 pts vs Nifty 500) · volume 1.3× usual · delivery +10.6 pts against usual · The announcement
Ajanta Pharma results filing dates and deadlines
Listed companies must file quarterly results within 45 days, and the year's within 60.
Days to fileDays to file. The days from the period's end to the day the results reached the exchange.DeadlineDeadline, days. The days the rules allow from the period's end: 45 for a quarter or half year, and 60 for the year and the March quarter filed with it. A company that listed after the period ended has until 21 days after its listing where that is later.